New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models
|
By LabMedica International staff writers Posted on 04 Oct 2023 |
|
A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work.
Gestalt Diagnostics (Spokane, WA, USA) has released the Mitotic Counting algorithm which has been trained on more than 100,000 individual mitosis and across seven scanner models. The algorithm performs impressively with an F1-Score of 0.74, matching the performance of top-of-the-line methods in the field. The algorithm is currently available in the Gestalt AI Studio for use on a variety of cancers including cutaneous mast cell tumors, breast cancer, lymphoma, lung cancer, melanoma, neuroendocrine, colon cancer, and bladder carcinoma. The algorithm has been trained on several scanner models, including those from Hamamatsu, Leica, 3D Histech, and Aperio.
Key to the broad applicability of deep learning algorithms is their ability to adapt to new scanners and different types of tissue; a broad dataset is crucial to achieve this goal. Gestalt Diagnostics' dataset encompasses seven types of tissues spanning eight tumors and is digitized with seven different scanner models. Additionally, Gestalt Diagnostics also offers PathFlow, a smart and customizable workflow solution that offers genuine interoperability for optimal efficiency. This solution supports both digital and glass slides and allows for tailored rules that can be can be configured to meet specific needs and requirements.
"What does this mean for our customers? Confidence,” said Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. “Gestalt is focused on providing solutions that provide a foundation of confidence in use as this industry continues to evolve, innovate, and incorporate products that are meant to enhance a pathologist's or scientist's daily life."
"We are extremely proud of the comprehensive approach we take to AI development as an organization,” added Brian Napora, Gestalt VP, AI Solutions. “Our position is to not only look at development and training with a small subset of images or on one or two scanners, that would not prove as effective or accurate as we feel our customers and the industry require. Therefore, we train on tens of thousands images, tumors cells, or in this case, mitosis and multiple scanner models across several scanner vendors to ensure the most accurate, clinically usable options for our customers."
Related Links:
Gestalt Diagnostics
Latest Pathology News
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
- CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
- Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
- AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
- Hybrid Computational Imaging Method Improves Digital Pathology Resolution
- FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
- New Review Highlights Intelligent Agents as Next Step for Digital Pathology
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Channels
Clinical Chemistry
view channel
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more
Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read moreMolecular Diagnostics
view channel
Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care
Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more
Molecular Skin Test May Help Guide Treatment Selection in Atopic Dermatitis
Patients with atopic dermatitis (eczema) often struggle to achieve consistent symptom control, leading many to alter or switch systemic therapies when treatment is ineffective. Newly published survey data... Read more
Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer
Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more
Genomic Breast Cancer Study Adds Real-World Evidence Across Diverse Patient Populations
Early-stage breast cancer treatment planning requires balancing recurrence risk, tumor biology, and the potential benefit of systemic therapy. These decisions can be challenging when certain patient groups... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
Microbiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Technology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Industry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
